Home › Chronic Lymphocytic Leukemia › Virginia › Charlottesville
Chronic Lymphocytic Leukemia clinical trials in Charlottesville, VA
3 studies for Chronic Lymphocytic Leukemia are looking for participants at sites in and around Charlottesville (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
RecruitingPhase 3
- University of Virginia Cancer Center ( Site 5402), Charlottesville
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
RecruitingPhase 2
- University of Virginia Medical Center, Charlottesville
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
RecruitingPhase 3
- University of Virginia Cancer Center ( Site 0040), Charlottesville
Chronic Lymphocytic Leukemia trials in other cities
- Boston, MA31 studies
- Columbus, OH29 studies
- Durham, NC28 studies
- Washington, DC22 studies
- Seattle, WA22 studies
- Rochester, MN20 studies
- New York City, NY20 studies
- Houston, TX18 studies
- Baldwin Park, CA18 studies
- Cincinnati, OH15 studies
- Milwaukee, WI15 studies
- Chicago, IL14 studies
Other studies in Charlottesville
- Non-Small Cell Lung Cancer22 studies
- Acute Myeloid Leukemia16 studies
- Prostate Cancer15 studies
- Endometrial Cancer15 studies
- Cancer (all types)14 studies
- Lung Cancer13 studies
- Metastatic Cancer12 studies
- Heart Failure11 studies
- Colorectal Cancer10 studies
- Pancreatic Cancer10 studies
- Ovarian Cancer9 studies
- Ischemic Stroke9 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.